Tuberculosis and beta-lactam antibiotics

Gun M. A., BOZDOĞAN B., ÇOBAN A. Y.

FUTURE MICROBIOLOGY, cilt.15, sa.10, ss.937-944, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 15 Sayı: 10
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2217/fmb-2019-0318
  • Dergi Adı: FUTURE MICROBIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.937-944
  • Anahtar Kelimeler: beta-lactams, MDR, tuberculosis, XDR, DRUG-RESISTANT TUBERCULOSIS, MEROPENEM-CLAVULANIC ACID, MYCOBACTERIUM-TUBERCULOSIS, IN-VITRO, ANTITUBERCULOSIS DRUGS, TREAT MULTIDRUG, COMBINATION, CARBAPENEMS, EFFICACY, SUSCEPTIBILITY
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Tuberculosis (TB) is one of the oldest health problems in the world and it remains unresolved. Multidrug-resistant-TB and extensively resistant-TB are a serious problem for control programs. The evaluation of available antibiotics has gained importance in recent years for the treatment of resistant TB. Beta-lactam antibiotics inhibit cell wall biosynthesis in the bacteria; the presence of beta-lactamase enzyme in TB bacilli raises the question of whether this group of antibiotics can be used in treatment. As a result, it has been reported that the combination of beta-lactam antibiotics with beta-lactamase is effective againstMycobacterium tuberculosisbothin vitroandin vivo. The aim of this article is to review and discuss up-to-date knowledge and future perspective on beta-lactam antibiotics and TB.